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Due to its aggressive and invasive nature glioblastoma (GBM), the most common
and aggressive primary brain tumour in adults, remains almost invariably lethal.
Significant advances in the last several years have elucidated much of the molecular
and genetic complexities of GBM. However, GBM exhibits a vast genetic variation
and a wide diversity of phenotypes that have complicated the development of
effective therapeutic strategies. This complex pathogenesis makes necessary the
development of experimental models that could be used to further understand the
disease, and also to provide a more realistic testing ground for potential therapies.
In this report, we describe the process of transformation of primary mouse embryo
astrocytes into immortalized cultures with neural stem cell characteristics, that are
able to generate GBM when injected into the brain of C57BL/6 mice, or heterotopic
tumours when injected IV. Overall, our results show that oncogenic transformation
is the fate of NSC if cultured for long periods in vitro. In addition, as no additional hit
is necessary to induce the oncogenic transformation, our model may be used to
investigate the pathogenesis of gliomagenesis and to test the effectiveness of dif-
ferent drugs throughout the natural history of GBM.
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1 | INTRODUCTION
Glioblastoma (GBM) is the most malignant and highly aggressive
type of gliomas, which accounts for almost 50% of primary ma-
lignant brain tumours in adults. However, it still carries a poor
prognosis, with a 5‐year survival of 4.7%, due to its aggressive
and invasive nature, and its remarkable heterogeneity (Jacob
et al., 2020; Joshi et al., 2015; Louis et al., 2016; Ostrom et al.,
2018; Patel et al., 2014). These characteristics complicate the
development of effective therapeutic strategies and compel the
need for more trustworthy models to study the disease and test
new drugs and therapies.
In vitro cultures are widely employed as suitable models to
investigate both the pathogenesis and the therapeutics of GBM,
although these models are imperfect for several reasons. Dif-
ferent lines of immortalized glioma cells, such as U87, U251,
T98G, or CT‐2A have been widely used for more than 30 years
(Caragher et al., 2019; Xie et al., 2015). However, although the
use of cell lines has provided valuable knowledge about GBM,
they undergo profound phenotypical changes when grown as
monolayers, and fail to develop the defining morphological fea-
tures of GBM tumours when injected in vivo. These cells also
exhibit markedly different responses to cytotoxic treatments
than those observed in patients, and controversy regarding their
origins has recently appeared (Allen et al., 2016).
On the other hand, the use of patient‐derived cells has be-
come the gold standard of GBM preclinical studies, mainly to test
personalized therapies, and a library of annotated and validated
cell lines derived from surgical samples of GBM patients has been
recently created (Jacob et al., 2020; Xie t al., 2015). It is expected
that the use of validated cells, together with novel culture sys-
tems that better recapitulate the complex reality of brain tu-
mours growing in situ (Caragher et al., 2019) may provide a more
suitable model for preclinical GBM research in the next future.
However, despite their clear benefits over some current models,
these models still have important limitations when investigating
the pathogenesis of GBM, as they are established from already
developed tumours, either spontaneously generated in a patient
or experimentally induced in a cell line or laboratory animal.
Therefore, it is very difficult to recapitulate the natural history of
the oncogenic process and identify molecular targets involved in
the early development of the disease.
In this study, we describe a novel cellular model that allows
investigating the transformation of mouse neural stem cells (NSC)
into aggressive GBM with metastatic capacity. Our results show that
oncogenic transformation occurs in immortalized NSC because of
long‐term passaging in vitro, and without the need of any external hit
other than the factors presented in a standard culture media. Fur-
thermore, this transformation occurred with a 100% frequency, in-
dicating that it is the fate of immortalized NSC in vitro, at least under
our experimental conditions. Whether a similar process may occur in
vivo, as a consequence of the dysregulation of the neurogenic niche,
remains to be elucidated.
2 | MATERIALS AND METHODS
2.1 | Cell cultures
Immortalized NSC were generated from 13.5 dpc (day post coitum)
C57BL/6 mice embryos, as previously described (Almengló et al.,
2020; Seoane et al., 2017). Briefly, pregnant C57BL/6 mice were
sacrificed at 13.5 dpc and uterine horns were then dissected. Each
embryo was separated from its placenta and embryonic sac and
transferred to an individual petri dish with Dulbecco's modified
Eagle's medium (DMEM; Sigma‐Aldrich). The head of each embryo
was individually transferred to fresh Petri dishes, and brains were
then isolated, finely minced, and dissociated by mechanical shearing,
followed by filtration through a 40‐micron mesh. Cells were plated in
Falcon polystyrene culture dishes (BD Biosciences) and grown in
DMEM supplemented with 10% foetal bovine serum (Thermo Fisher
Scientific), 2 mM glutamine, 2.5 U/ml penicillin, and 2.5mg/ml
streptomycin (all from Thermo Fisher Scientific). Cultures were
maintained at 37°C in a humidified atmosphere of 5% CO2. This
method has been proved to consistently yield more than 95% of glial
fibrillary acidic protein (GFAP) + primary mouse embryo astrocytes
(MEA) (Almengló et al., 2017, 2020; Seoane et al., 2017). Im-
mortalization of primary MEA was achieved by using the 3T3 pro-
tocol (Todaro & Green, 1963) with appropriate modifications
(Almengló et al., 2020). Cells were transferred to new dishes with
fresh medium every 3 days, with the same cell density (3 × 103/cm2)
seeded in every transfer. Continual cell passaging was used to gen-
erate long‐term cultures of low passage (LP)‐immortalized cells
(below 20 passages) or high passage (HP)‐immortalized cells (40–100
passages) (see Figure 1 for further details). Both the immortalization
protocol and the long‐term maintenance of immortalized cells were
carried out in DMEM. Formation of neurospheres was induced by
using a modification of the neurosphere assay (Almengló et al., 2017;
Azari et al., 2011). In this case, cells growing in DMEM were tryp-
sinized and transferred to fresh polystyrene culture dishes (ap-
proximately 3 × 105/dish) with semisynthetic (neurobasal) medium
supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 1%
Gibco B27 supplement, 10 ng/ml bFGF, and 10 ng/ml EGF (NBE
conditions) (Lee et al., 2006). As immortalization occurred with a
100% frequency, and no differences were observed in the outcome
of the cells, results obtained with different batches of immortalized
NSC are presented throughout this study.
To ensure the detection of the immortalized cells after injection
in mice, and to rule out a spontaneous origin of the generated tu-
mours, luminescence and fluorescence reporter systems were de-
veloped. To create the luminescence reporter, the pBABE‐puro‐Luc
vector was transfected into Phoenix ecotropic retroviral packaging
cells (a gift from C. Watzl) (Swift et al., 2001) by using the JetPEI
polyplus transfection system (Illkirch, France). Retroviruses‐
containing supernatant was collected 48 h after transfection and
used to infect immortalized cell cultures, using polybrene (5 μg/ml)
as transduction enhancer. Cells were then selected for 48 h with
2.5 μg/ml puromycin, and infection efficiency was measured by
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quantifying the luciferase activity using an optical in vivo imaging
system (IVIS Spectrum, Perkin‐Elmer). A red fluorescence reporter
gene was created by replacing the sequence coding for GFP in a
pMSCV PIG vector (Puro IRES GFP empty vector) with the sequence
encoding the monomeric far‐red fluorescent protein TagFP635 from
a pTagFP635‐C vector. The new vector was transfected into Phoenix
ecotropic retroviral packaging cells and the supernatant was used to
infect immortalized cells, as indicated before.
2.2 | Generation of orthotopic tumours
Orthotopic tumours were generated by stereotaxic injection of im-
mortalized NSC. Six‐week‐old C57BL/6 male mice were anesthetized
by intraperitoneal injection of a ketamine (80–100mg/kg) and xy-
lazine (16–20mg/kg) mixture and returned to a holding cage briefly
before being placed on a stereotaxic frame (David Kopf Instruments).
The surgical area was carefully scrubbed, and a sagittal incision was
made through the scalp. The periosteum was then retracted by
gently rubbing and microinjections were made in the brain par-
enchyma according to a topographical map (Paxinos & Franklin,
2019) (coordinates: anterior −0.2mm, lateral 1 mm from bregma and
depth 2.2 mm from the skull surface) by using a 25‐gauge needle
(Hamilton 7001 syringe, Hamilton Company). The needle was gently
inserted into the skull opening, retracted to accommodate the in-
jection volume (5 μl), and the cell suspension (1 × 105 cells) was
slowly injected. Once the microsyringe was removed, the head skin
was sutured with surgical silk. Mice were monitored for anaesthetic
recovery and postsurgical pain. To obtain GBM‐derived cell cultures,
tumours were finely minced and dissociated by mechanical shearing
as indicated above. Cell cultures were grown in DMEM as described
and neurosphere generation was induced by placing the cells in NBE
conditions.
2.3 | Generation of heterotopic (metastatic)
tumours
To investigate the hematogenous dissemination of either
HP‐immortalized cells or GBM‐derived cells, 3‐week‐old male mice
were anesthetized with isoflurane (3% v/v), placed in a restrainer,
and injected with the corresponding cell suspension (3 × 105 cells
diluted in 500 µl of saline solution). Cells were injected in the caudal
vein with a 25‐gauge needle, and animals were monitored for
5–10min to ensure haemostasis. Cell cultures from macroscopic
metastatic lung tumours were performed as described. After care-
fully dissecting the tumours from the surrounding tissue, they were
finely minced and dissociated by mechanical shearing. Cell cultures
were grown in DMEM and neurosphere generation was induced by
placing the cells in NBE conditions.
To test the presence of micrometastasis in several organs, cell
cultures from lung, kidney, spleen, brain, bone marrow, testicles, and
F IGURE 1 Experimental design used for the generation of the different cell types investigated. Primary cultures of MEA obtained from 13.5
dpc mouse embryos (1) were submitted to a 3T3 protocol, resulting in the generation of immortalized NSC (low passage) (2). Immortalized NSC
can proliferate indefinitely, leading to high‐passage‐immortalized NSC (3). Orthotopic injection of high‐passage‐immortalized NSC in mice
resulted in the generation of GBM (4); while IV injection of high‐passage‐immortalized NSC in the tail vein resulted in the formation of
heterotopic (metastatic) tumours (5). Finally, formation of heterotopic (metastatic) tumours was also observed after IV injection of
GBM‐derived cells (6). As indicated in the figure, the capacity to form neurospheres was assessed in every cell type. GBM,; MEA, mouse embryo
astrocyte; NSC,;
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liver were performed. Except for bone marrow, tissues were finely
minced and dissociated as described. Form bone marrow cultures,
femora and tibiae of the mice were harvested and flushed using
phosphate‐buffered saline (PBS) in a 1‐ml syringe with a 25‐gauge
needle. Cells were collected by centrifugation and seeded. In all
cases, cultures were grown in DMEM, and neurosphere generation
was induced by placing the cells in NBE conditions.
2.4 | In vivo imaging
For in vivo monitoring of tumoral growth, luciferin was injected in-
traperitoneally at a dose of 10 μl/g body weight. Mice were then
anesthetized with isoflurane (3% v/v) and placed on the imaging
stage of an optical imaging system (IVIS Spectrum). Images were
collected every minute from 15 to 30min after luciferin injection,
and photon emission was quantified using Living Image Software
(Living Image 3.1; PerkinElmer).
2.5 | Immunocytochemistry
For immunocytochemical analysis, approximately 5 × 103 cells were
seeded in glass coverslips, placed in 24‐multiwell plates, and in-
cubated for 24 h, as described above. Cells were then fixed in 96%
ethanol for 1 h, rinsed in PBS, and permeabilized by adding 250 µl of
0.1% TritonX‐100, 0.3% bovine serum albumin for 1 h. After rinsing
the cells three times in PBS, an overnight incubation at 4°C was
performed with the following primary antibodies: anti‐glial fibrillary
acidic protein (Dako, Agilent Technologies; ready to use), anti‐myelin
basic protein (MBP; dilution 1:2000; Dako, Agilent Technologies),
anti‐nestin (dilution 1:200; Merk Millipore), anti‐RFP (βIIIT; dilution
1:2000; Dako, Agilent Technologies), and anti‐Ki67 (dilution 1:1000;
Seven Hills Bioreagents). Positive cells were detected with a
universal second antibody kit that uses a peroxidase‐conjugated
labelled dextran polymer (EnvisionPlus, Dako, Agilent Technologies)
and photographed with an Olympus BX43 camera (Olympus
Optical Co.).
2.6 | Immunohistochemistry
For histological evaluation, tissues were fixed by immersion in 10%
buffered formalin for 24 h, then dehydrated in ethanol (70%) for
24 h, and embedded in paraffin using a standard procedure. Serial
4‐µm sections were consecutively cut with a microtome (Leica
Microsystems GmbH) and transferred to adhesive‐coated slides.
Immunohistochemistry was performed with a universal second an-
tibody kit that uses a peroxidase‐conjugated labelled‐dextran poly-
mer (Envision Plus, Dako). The following primary antibodies were
used: anti‐glial fibrillary acidic protein (Dako, Agilent Technologies;
ready to use), anti‐myelin basic protein (Dako, Agilent Technologies;
dilution 1:2000), anti‐nestin (Merk Millipore; dilution 1:200), anti‐
RFP (Dako, Agilent Technologies; dilution 1:2000), and anti‐Ki67
(dilution 1:1000; Seven Hills Bioreagents). Overnight incubation at
4°C was performed with every antibody. For negative controls, each
staining run was incubated with normal rabbit serum instead of the
primary antibody. Counterstaining was performed with hematoxylin‐
eosin staining.
2.7 | Real‐time polymerase chain reaction (PCR)
Total RNA was isolated from the different cell cultures by using
TRIzol (Invitrogen). cDNA was synthesized with the Transcriptor
first‐strand cDNA synthesis kit (Roche Diagnostics), and real‐time
PCR was performed using SYBR Green Master Mix (Applied Bio-
systems) with an iCycler equipment (7500 PCR Systems, Applied
Biosystems). Samples were denatured at 95°C for 15 s, annealed at
55 s, for 15 s, and extended at 72°C for 40 s, for a total of 40 cycles.
The Sequence detection software 1.4 (Applied Biosystems) was used
for quantification, using GAPDH as control. The oligonucleotide se-
quences used are: GAPDH forward: AGGTCGGTGAACGGATTTG;
GAPDH reverse: GGGGTCGTTGATGGCAACA; GFAP forward:
TCGCTTTCCTCTGAACGCTTCTCG; GFAP reverse: TCTGAACGC
TGTGACTTGGAGTTCC; MBP forward: CCAAGTTCACCCCTACT
CCA; MBP reverse: AGGGGGAAGAAAACAAAGGA; nestin forward:
CCCTGAAGTCGAGGAGCTG; nestin reverse: CTGCTGCACCT
CTAAGCGA. Statistical analysis was performed with the nonpara-
metric test of Kolmogorov‐Smirnov. Statistical significance was es-
tablished at p < .05.
2.8 | Metaphase chromosome preparation
Metaphase spreads were prepared after treating the cells with col-
cemid (0.1 µg/ml; Sigma‐Aldrich) for 7 h. Cells were then incubated in
hypotonic buffer (0.05M KCl, 0.0034M trisodium citrate) for 20min
at 37°C and fixed in 75% methanol, 25% acetic acid. Cells were then
spotted onto microscope slides and stained with 2% Wright stain
(0.1 µg/ml; Sigma‐Aldrich) in Gurr buffer, pH 7.0 (Invitrogen).
Metaphase chromosomes were scored using a Leica 2005 micro-
scope under a 100X oil objective lens. At least 50 metaphases were
analysed from three independent experiments.
2.9 | Cell proliferation assay
Cells were seeded at 10 × 103 (primary), 5 × 103 (immortalized
low passage) or 2.5 × 103 (immortalized HP, GBM‐derived and
metastasis‐derived) and grown in DMEM for 1, 3, 5 or 7 days.
At these times, cells were fixed and stained with 0.1% violet
crystal (Sigma‐Aldrich) for 30 min and then washed with PBS to
remove the dye excess. Dye content was quantified in a spec-
trophotometer. To determine the rate of BrdU incorporation, 106
cells were seeded in poly‐L‐lysine‐coated slides (1 ml/slide) and
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maintained for 24 h. Cells were grown in the presence of BrdU
(10 mM; Sigma‐Aldrich) for 2.5 h, and BrdU+ cells were detected
by immunocytochemistry using a monoclonal antibody (dilution
1:2000; BD Biosciences). Representative images were captured
with an Olympus DP72 camera (Olympus Optical Co.), and the
number of BrdU+ cells was quantified in 10 random fields per
slide.
2.10 | Dot blot assay
A multiplexed protein detection kit (C‐Series Human/Mouse AKT
Pathway Phosphorylation Array C1, RayBiotech) was used to
investigate the existence of changes in the signalling machinery
among the different cell types generated. All procedures were
performed according to the manufacturer's instructions Briefly,
cells were washed with ice‐cold PBS and solubilized in lysis
buffer. Cell lysates were then centrifuged (14,000 rpm, 5 min,
4°C) and protein concentration was determined using the
Bradford assay (Bio‐Rad Laboratories). Membranes were blocked
for 30 min at room temperature and incubated overnight at 4°C
with 200 μg of each sample, before incubation with the detection
antibody cocktail (2 h at room temperature). Immunoreactivity
was detected by chemiluminescence using X‐ray film (Fuji
Medical) to visualize the dots. Images were analysed with the
ImageJ open‐source image software (https://imagej.nih.gov/ij/).
Data were corrected for the local background and normalized for
positive and negative internal controls.
2.11 | Study approval
All animal procedures were approved and performed according to
the guidelines set out by the Institutional Ethics Committee for
Animal Experimentation (protocol No 15005AE/07/FUN01/FIS02/
JACP1).
3 | RESULTS
3.1 | Generation of NSC with the capacity to
generate GBM in vivo
In keeping with our previous report (Almengló et al., 2017), both
LP‐ and HP‐immortalized cultures obtained from mouse embryo
brains retain their capacity to express specific markers for all neural
lineages (data not shown). Also in concordance with our previous
findings, neurosphere formation can be induced by placing the cells
under NBE conditions (data not shown). Altogether, these char-
acteristics indicate that both types of cultures can be considered as
bona fide immortalized NSC.
In addition, we also reported previously that HP‐immortalized
NSC show a sharp increase in their proliferative rate, as compared
with either primary or LP‐immortalized cells, together with the
presence of numeral chromosomal abnormalities (Almengló et al.,
2017). As these phenotypical traits may indicate a potential for
cellular transformation, in the present study, we first investigated
their capacity to generate brain tumours in vivo. To this end, cell
suspensions of either LP‐ or HP‐immortalized NSC were injected into
the cerebral parenchyma of C57BL/6 mice. As Table 1 shows, de-
velopment of orthotopic tumours was observed in all mice injected
with HP‐immortalized NSC (40, 60, or 90 passages), as soon as 3.5
months of injection (see also Figure 2a). In contrast, no tumours were
observed in mice injected with either primary cultures or LP (15
passages) immortalized cells. The tumours showed many of the dis-
tinctive characteristics of GBM (Louis et al., 2016) including an in-
fliltrative growth pattern, marked cellular pleomorphism, and the
presence of regions of necrosis. Extensive vascular hyperplasia,
thrombus formation, and invasion of vessel walls, together with
prominent Ki67 expression (Figure 2b,d) were also present. In con-
trast, neither GFAP nor MBP expression was detected (Figure 2c), a
finding in keeping with previous reports indicating that GBM typi-
cally displays loss of glial marker expression, including GFAP (Louis
et al., 2016). Demonstration that tumours are not spontaneously
generated but arise from the injected cells was obtained by detecting
the expression of RFP in the tumour cells (Figure 2e).
To further characterize the generated tumours, we investigated
their ability to retain bona fide NSC features in vitro. As occurs with
immortalized NSC, cells isolated from GBM can grow as a monolayer
culture, that can be induced to form neurospheres by placing them in
NBE conditions (Figure 3a,b). Also, in keeping with the results
TABLE 1 Generation of GBM in mice after orthotopic injection
of primary (1), low passage‐immortalized NSC (2) or high‐passage‐
immortalized NSC (3) (see Section 2 for further details)
Mice No. Cell type (passages) Time to tumour
1 1 (‐) No tumour
2 1 (‐) No tumour
3 2 (15) No tumour
4 2 (15) No tumour
5 3 (40) 3.5 months
6 3 (40) 3.5 months
7 3 (40) 3.5 months
8 3 (60) 3.5 months
9 3 (60) 3.5 months
10 3 (60) 3.5 months
11 3 (90) 3.5 months
12 3 (90) 3.5 months
13 3 (90) 3.5 months
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obtained in immortalized NSC, GBM‐derived cells retain their ca-
pacity to express specific markers from all three neural lineages
(Figure 3b,c), although a prominent decrease in GFAP expression was
observed in this case. As expected, GBM‐derived cells are also cap-
able of inducing the formation of GBM in mice after orthotopic in-
jection (Figure 3d,e), which can be detected in vivo as soon as 1
month after the injection. Histological and immunohistochemical
analysis of these GBM were almost identical to those of the tumours
generated after orthotopic injection of HP‐NSC, including the lack of
expression of both GFAP and MBP (data not shown).
3.2 | Generation of NSC with the capacity to
generate heterotopic (metastatic) tumours in vivo
One of the more intriguing aspects of the biology of GBM is their ability
to form metastasis, most likely because of the notion that extracranial/
extraspinal metastases of human GBM are clinically rare (Awan et al.,
2015; Goodwin et al., 2016; Hoffman et al., 2017; Taskapilioglu et al.,
2013). Therefore, we took advantage of our cellular model to investigate
the ability of either HP‐immortalized NSC or GBM‐derived cells to form
metastatic (heterotopic) tumours in vivo after injection in the tail vein of
C57BL/6 mice. As Table 2 shows, macroscopic lung tumours were ob-
served in all mice injected with HP‐immortalized NSC (four mice) after 6
months of injection. In contrast, no tumours were detected after 3 or 4
months of injection of HP‐immortalized NSC. In addition, a macroscopic
lung tumour was also detected in one of three mice injected with
GBM‐derived cells, although, in this case, the tumour developed as soon
as 3 months after injection (Table 2 and Figure 4a). Macroscopic ex-
amination of metastatic lungs showed the presence of single or multiple
metastatic nodules with cannonball appearance and frequent haemor-
rhagic foci (Figure 4b), which was more clearly evidenced after low
magnification of haematoxylin and eosin stating of the lung (Figure 4c).
Microscopic examination of the tumours showed the distinct character-
istics of GBM‐derived cells when analyzed at higher magnification. These
include the presence of marked cellular pleomorphism and necrosis
F IGURE 2 Generation of GBM in mice after orthotopic injection of high‐passage‐immortalized NSC. Cell suspensions of 3 × 105 cells
obtained from primary cultures, low‐passage‐immortalized NSC (15 passages) or high‐passage ‐immortalized NSC (40, 60, or 90 passages) were
injected into the brain of C57BL/6 mice. (A) In vivo fluorescence imaging of one tumour generated 3.5 months after the injection. A more
detailed ex vivo image of the brain is shown in the insert. (B) Representative haematoxylin‐eosin staining showing some of the pathological
hallmarks of GBM, including the marked cellular pleomorphism, and the presence of regions of extensive vascular hyperplasia, vascular
invasion, and necrosis. (C) Immunohistochemical staining showing the absence of either GFAP or MBP expression in tumour cells, as compared
with the prominent expression of both markers in the nearby normal brain. (D) Immunohistochemical detection of Ki67 shows increased
expression in GBM (left), as compared with negative controls (right). (E) Demonstration that GBM arise from injected cells was obtained by
immunohistochemical detection of the RFP protein (left), while no RFP expression was detected in negative controls (right). GBM,; GFAP, glial
fibrillary acidic protein; MBP, myelin basic protein; NSC,; RFP,;
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(Figure 4d), together with the existence of prominent Ki67 expression
(Figure 4e). As in the case of primary brain tumours, neither GFAP nor
MBP expression was detected in tumoural cells (Figure 4f). Also in this
case, a demonstration that metastatic (heterotopic) tumours arise from
injected cells was obtained by investigating the existence of RFP ex-
pression (Figure 4g). Furthermore, cells isolated from metastatic tumours
can grow as monolayer cultures that can be induced to form neuro-
spheres when placed in NBE conditions (Figure 5a). As also occurs with
GBM‐derived cells, cells obtained from heterotopic tumours retained the
expression of specific markers for all neural lineages (Figure 5a and b),
with a sharp decrease in the case of GFAP (Figure 5b).
Despite the low rate of extracranial metastasis that exists in GBM,
recent reports have described the existence of circulating tumour cells
(CTC) in the peripheral blood of patients with GBM (Awan et al.,
2015;@@ Li et al., 2017; Seoane & De Mattos‐Arruda, 2014). Therefore,
to further investigate the blood dissemination of the injected cells, we
performed cellular cultures of the brain, kidney, spleen, bone marrow,
testicles, and liver, obtained from mice injected with either HP‐
immortalized cells or GBM‐derived cells. In all cases, the presence of
tumoral cells in these tissues was demonstrated by growing primary
cultures in DMEM, and inducing the formation of neurospheres by pla-
cing them in NBE conditions. Although macroscopic tumours were not
detected in any of those organs, formation of neurospheres and, there-
fore, evidence of the existence of microscopic heterotopic tumours was
found in the kidney (Figure 6), liver, and spleen (Table 2). In addition, lung
microscopic metastasis were also found in two mice with the absence of
macroscopic lung tumours (Table 2). In contrast, generation of neuro-
spheres was not observed, in any case, in primary cultures from bone
marrow, testicle, or brain. As expected, neurospheres expressed specific
markers for all neural lineages, though GFAP expression was also sharply
reduced in this case (Figure S1).
3.3 | Phenotypical characterization of
immortalized, tumoral and metastatic NSC
Altogether, our results demonstrate that continual passaging of cell
cultures obtained from mouse embryo brain results in the generation
of immortal cells with NSC characteristics that, finally, acquire the
capacity to generate both primary GBM and heterotopic tumours in
F IGURE 3 Cells derived from GBM retain NSC characteristics. GBM were dissociated and cells were grown in DMEM (see materials and
methods for further details). Neurosphere formation was induced by placing the cells in NBE conditions. (A) Neurosphere formation was
induced by placing the cells in NBE conditions. (B) Expression of specific markers of neural lineage (GFAP, MBP, and nestin) was detected by
immunocytochemistry (lower panels are the negative controls). (C) Expression of specific neural markers was also demonstrated by
semiquantitative RT‐PCR (in this case, primary cells were used as control). (D, E) Real‐time bioluminescent imaging of the tumoral growth in
vivo, after orthotopic injection of GBM‐derived cells. Results in (D) are the mean ± SEM of six animals. Representative imagens are shown in (E).
DMEM,; GBM,; NBE,; NSC,; RT‐PCR,;
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vivo. Therefore, to better understand the mechanisms underlying
this transformation, we next investigated the presence of cellular
aneuploidy, one of the hallmarks of the oncogenic process (Duesberg
et al., 1998; Li et al., 1997; Rasnick & Duesberg, 1999). As Figure 6
depicts, more than 80% of primary cells have 40 chromosomes, but a
sharp increase in the number of numerical chromosome abnormal-
ities is observed in immortalized cells, even in LP cells. This finding is
in concordance with our previous reports (Almengló et al., 2020) and
indicates that hyperploidy is an early event within the transforma-
tion process of NSC. Although the percent of cells with severe
polyploidy is greater in HP‐immortalized or in tumoral (either pri-
mary or heterotopic) cells, the most striking changes occur soon after
immortalization is achieved.
These changes in cellular aneuploidy correlate with other phe-
notypical and biochemical modifications observed. When compared
with primary cells, both LP‐ and HP‐immortalized cells showed an
increase in their proliferation rate (Figure 7a,b), a finding that is also
in keeping with our previous results (Almengló et al., 2020). Inter-
estingly, the increase in growth rate observed in HP‐immortalized
cells is similar to that observed in GBM‐derived cells (Figure 7a,b),
and contact inhibition was preserved in both cases (data not shown).
However, the highest proliferative rate was observed in cells
obtained from heterotopic tumours, either generated from
HP‐immortalized cells or GBM‐derived cells (Figure 7a,b). These
differences in cell proliferation sharply correlate with the changes
observed in the expression of Ki67 and in the rate of BrdU in-
corporation. In fact, while <50% of either primary or LP‐immortalized
cells show immunoreactivity to Ki67, more than 90% of
HP‐immortalized or GBM‐derived cells, and virtually all cells derived
from heterotopic tumours are Ki67+ (Figure 7c). In the case of BrdU
incorporation, a significant increase was already observed in
LP‐immortalized cells when compared with control cells, but the
most striking boost was found in HP‐immortalized NSC. BrdU uptake
remained similarly increased among all tumour‐derived cell types,
either primary or metastatic (Figure 7d). Also in keeping with our
previous findings, continual cell passaging resulted in the appearance
of dramatic morphological changes. Although flat, polygonal cells
were still present in hastily growing cells, most of them displayed
distinct morphological modifications, including the presence of mul-
tinucleated cells with very large cytoplasms and long thin projections
(data not shown).
3.4 | Biochemical characterization of
immortalized, tumoral and metastatic NSC
Finally, we investigated the biochemical changes underlying the
timeline of the modifications that led to the transformation of pri-
mary cells into GBM‐producing cells. Although GBM displays a het-
erogeneous profile, a common feature of all GBM types is an
aberrant kinase signalling, and among the pathways implicated, the
RAS‐mitogen‐activated protein kinase (MAPK), is one of the most
frequently dysregulated in GBM cells (Hannen et al., 2017; Lo, 2010;
Mao et al., 2012). In keeping with this, undetectable levels of either
Raf‐1 or ERK1 phosphorylation were observed in both primary cul-
tures and LP‐immortalized cells (Figure 8a), while a clear rise was
detected in HP‐immortalized cells. Furthermore, this activation was
progressively increasing throughout the transformation process,
with the highest phosphorylation levels found in cells from hetero-
topic tumours. A similar pattern of activation was observed in the
case of the two leading members of the RSK (90 kDa ribosomal S6
kinase) family, RSK1 and RSK2, two downstream effectors of the
ERK pathway (Romeo et al., 2012) (Figure 8a). RSK1 phosphorylation
was undetectable in either primary or LP‐immortalized cells, but
progressively increased in the other cell types, with the highest
phosphorylation levels detected in cells from heterotopic tumours. In
the case of RSK2, no phosphorylation was detected in primary, LP‐
immortalized, and HP‐immortalized cells, and phosphorylation levels
were also unexpectedly low in cells from heterotopic tumours ori-
ginated from HP‐immortalized NSC. Interestingly, although both
RSK1 and RSK2 are associated with glioma malignity, RSK1 has been
described as a potential progression marker and a therapeutic target
for gliomas. In fact, RSK1 phosphorylation levels (Ser380), which
more specifically reveals ERK activation, are higher in GBM (Hajj
et al., 2020). Additionally, RSK1 phosphorylates p27 at Thr198,
leading to accumulation of phosphorylated p27 in the cytoplasm
(Larrea et al., 2009). Accordingly, p27 levels progressively increased
with a similar pattern to that observed in RSK‐1. These findings,
TABLE 2 Generation of metastatic tumours in mice after IV
injection of high‐passage‐immortalized NSC (cell type 3) or GBM‐






1 3 (40) 4 No tumour
2 3 (40) 4 No tumour
3 3 (40) 6 Lung, kidney,*
spleen*
4 3 (40) 6 Lung
5 3 (60) 4 No tumour
6 3 (60) 4 No tumour
7 3 (60) 4 No tumour
8 3 (90) 3 No tumour
9 3 (90) 4 No tumour
10 3 (90) 6 Lung, kidney*
11 3 (90) 6 Lung, liver*
12 4 3 Lung,* liver*
13 4 3 Lung
14 4 3 Lung,* liver*
Note: *denote the presence of microscopic tumours.
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together with the increased levels of p53 detected, may suggest that,
as we have previously shown (Seoane et al., 2017), increased cell
proliferation (and, eventually, cell transformation) may occur despite
the existence of a normal activation of the cellular checkpoints in-
volved in the induction of senescence. Surprisingly, a so clear pattern
of activation was not observed when other signalling pathways were
investigating. This is the case of the phosphatidylinositol 3‐kinase
(PI3K)‐Akt pathway that is activated in almost 90% of all GBM (Li
et al., 2016; Sami & Karsy, 2013; Sanai et al., 2004). However, we
were unable to find any difference in the phosphorylation level of the
leading members of this pathway, including PI3K, Akt, phosphatase
and tensin homolog (PTEN) or mammalian Target of rapamycin
(mTOR) (Figure S2), among the different cell types. Overall, these
results indicate that immortalization of NSC may be associated with
a progressive activation of the Ras/Raf/ERK signalling pathway.
4 | DISCUSSION
In the present study, we have demonstrated that continual pas-
saging of immortalized NSC results in their transformation into
cells that are able to produce either GBM or heterotopic tu-
mours, when injected in adult mice. Although further studies are
still necessary, our results support a role for NSC in the patho-
genesis of GBM, at least for primary GBM, which accounts for
more than 90% of this type of tumours (Joshi et al., 2015). This
proposal is in keeping with other studies indicating that NSC may
be the cells from which GBM originate, due to their self‐renewal
and proliferative capacities, and the relevance of the accumula-
tion of somatic mutations in the process of gliomagenesis (Al-
cantara Llaguno et al., 2009; Batlle & Clevers, 2017; Richards
et al., 2021; Sanai et al., 2004).
F IGURE 4 Generation of metastatic lung tumours in mice after heterotopic injection of high‐passage‐immortalized or GBM‐derived cells.
Cell suspensions of 3 × 105 cells obtained from either high‐passage‐immortalized NSC (90 passages) or GBM‐derived cells were injected in the
tail vein C57BL/6 mice. (A) Ex vivo fluorescence imaging of a metastatic lung after 6 months of heterotopic cell injection. (B) Macroscopic
aspect of one representative metastatic lung. Notice the presence of cannonball‐like tumours (yellow arrows), together with the existence of
haemorrhagic areas (red arrows). (C) Low magnification image of an entire haematoxylin‐eosin stained section revealing the presence of
multiple metastasis. (D) Haematoxylin‐eosin staining reveals the presence of blood vessels surrounding the micro metastases in addition to the
tumour's own vasculature. (E) Immunohistochemical detection of Ki67 shows increased expression in the tumour (left), as compared with the
negative control (right). (F) Immunohistochemical staining showing the absence of either GFAP or MBP expression in tumour cells.
(G) Demonstration that GBM arise from injected cells was obtained by immunohistochemical detection of the RFP protein (left), while no RFP
expression was detected in the negative control. GBM,; NSC,; RFP,;
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The role of embryonic stem cells in cancer has been largely
debated. Cancer initiating cells or cancer stem cells (CSC) are a
subpopulation of cells that has the driving force of carcinogenesis
(Alcantara Llaguno et al., 2009; Batlle & Clevers, 2017) that can be
identified in most types of human cancer (Bonnet & Dick, 1997;
Chang, 2016; Smith et al., 2008; Tomasetti et al., 2017). Although not
all CSC are originated from embryonic cells, specific criteria to define
CSC include (1) the ability to self‐renew; (2) the capacity to differ-
entiate into different lineages (multipotency); and (3) the ability to
initiate tumours in animal models, which recapitulate the original
disease phenotype and heterogenicity (Doherty et al., 2016; Sawada
& Sawamoto, 2013; Singh et al., 2004; Takaishi et al., 2009). All these
criteria are fulfilled by the HP‐immortalized NSC used in this study
and, therefore, they can be considered as truly CSC, thus supporting
the hypothesis of NSC as the source of GBM. In this regard, it has
been recently demonstrated that astrocyte‐like NSC in the SVZ are
the cell of origin that contains the driver mutations of human GBM
(Lee et al., 2018). Furthermore, astrocyte‐like NSC that carry driver
mutations migrate from the SVZ and lead to the development of
high‐grade malignant gliomas in distant brain regions (Lee
et al., 2018).
Of special interest is the fact that no “external” hit is needed to
induce the malignant transformation of NSC, other than their
continuous passaging and the stress induced to overcome replicative
senescence (Almengló et al., 2020). In fact, in contrast with the re-
sults reported in MEF placed on a 3T3 protocol, in which immortal
cells emerge at low frequency (Todaro & Green, 1963), we were able
to generate immortal NSC with a 100% frequency. Furthermore, all
HP‐immortalized NSC were able to generate GBM when orthotopi-
cally injected in mice. Therefore, it is tempting to speculate that the
mechanisms that allow primary cells to escape from replicative se-
nescence are those leading to malignant transformation. In this
context, it is interesting to note that those NSC that can overcome
replicative senescence show increased activation of both p27 and
p53 (Almengló et al., 2020, and the present work). This result, to-
gether with the early occurrence of hyperploidy in immortalized NSC
may suggest the existence of an uncoupled response to the activa-
tion of the DNA damage response (DDR). Interestingly, similar re-
sults have been previously reported by our group in response to
oncogene‐induced senescence (OIS) in primary MEA (Seoane et al.,
2017). In those cells, activation of Ras and elimination of RB does not
induce cellular senescence, despite the activation of the cellular
checkpoints related to DDR. It must be emphasized that MEA are the
cells that give rise to immortal NSC after overcoming replicative
senescence (Almengló et al., 2017, 2020, and the present study).
Therefore, the ability of MEA to escape cellular senescence, either
replicative or OIS, could underlie an important role in gliomagenesis.
Although we do not presently know the mechanisms involved in
this defective response, it is interesting to notice that the transition
from primary to immortalized cells is associated with an almost total
loss of euploid cells. Aneuploidy is one of the hallmarks of most
human cancers, with around 90% of all solid tumours being aneu-
ploid, mostly hyperdiploid (Coward & Harding, 2014; Duensing &
Duensing, 2010; Weaver & Cleveland, 2008). Although both the
mechanisms leading to aneuploidy and their consequences on tu-
morigenesis are still controversial, it has been proposed that tumour
cells with significantly elevated genomic content (polyploid tumour
cells) facilitate rapid tumour evolution. Furthermore, aneuploidy has
been shown to precede transformation in a variety of cancers
(Cardoso et al., 2006; Doak et al., 2004; Dooley et al., 1993; Ried
et al., 1999), and it has been proposed a role of aneuploidy during
tumour initiation (Duesberg et al., 1998; Li et al., 1997). In keeping
with this, severe polyploidy was also an early event in the natural
history of the transformation process described in the study, so it
can be hypothesized that it may be involved in the appearance of the
other biochemical and phenotypical changes observed, including the
increased activation of ERK signalling (Furgason et al., 2014; Jun
et al., 2018).
It remains to be elucidated whether similar mechanisms may
account for the oncogenic transformation of NSC in vivo. Under
physiological conditions, NSC are regulated by the orchestration of
intrinsic and extrinsic signals that provide the complex regulatory
architectures present in the neurogenic niche. The special micro-
environment defined within the neurogenic niche permits the
maintenance of the NSC pool and prevents terminal differentiation,
thus allowing the balance between cell loss and cell replacement in
F IGURE 5 Cells derived from lung metastatic tumours display
NSC characteristics. Lung tumours were dissociated, and cells were
grown in DMEM (see materials and methods for further details).
(A) Neurosphere formation was induced by placing the cells in NBE
conditions. Expression of specific markers of neural lineage
(GFAP, MBP, and nestin) was detected by immunocytochemistry in
cells derived from metastatic lung tumours. Lower panels are the
negative controls. Notice the presence of neurospheres attached to
the culture dish in all cases. (B) Expression of specific neural markers
was also demonstrated by semiquantitative RT‐PCR (in this case,
primary cells were used as control). Notice the reduced expression of
GFAP, as observed in GBM. DMEM,; GBM,; GFAP, glial fibrillary
acidic protein; MBP, myelin basic protein; NSC,; RT‐PCR,;
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the central nervous system (Arce et al., 2013; Gage, 2000; Vining &
Mooney, 2017). Under our experimental conditions, cells are grown
in the presence of FBS and, therefore, exposed, for a long time, to a
wealth of growth factors that are not present within the neurogenic
niche. Therefore, it is tempting to speculate that disturbance of the
microenvironment within the neurogenic niche may result in a dys-
regulated proliferation of NSC that, eventually, may cause the ap-
pearance of a GBM. In this respect, it has been shown that NSC
niches of the human brain may be a mutational source for brain
somatic mutations (Coward & Harding, 2014). Furthermore, a recent
report (Richards et al., 2021) directly links the healing process that
follows a brain injury with the spur of GBM, when new cells gener-
ated to replace those lost to the injury are derailed by mutations.
Another interesting conclusion of this study is the capacity of im-
mortalized NSC to disseminate and form heterotopic tumours when in-
jected in mice. Extracranial/extraspinal metastasis is a very uncommon
entity in GBM, and only a low number of patients develop extracranial
metastasis (Awan et al., 2015; Goodwin et al., 2016; Hoffman et al., 2017;
Taskapilioglu et al., 2013). Although, historically, GBM were not believed
to metastasize because of the presence of the blood‐brain barrier, im-
provements in the treatment of primary GBM has led to an increased in
reported metastasis, mostly in the lungs, but also in other organs such as
lymphatic nodes, bone, or liver (Awan et al., 2015; Goodwin et al., 2016;
Hoffman et al., 2017; Taskapilioglu et al., 2013). In keeping with this, we
found that lungs were the organs that more frequently presented het-
erotopic tumours (macroscopic and microscopic), but a widespread he-
matogenic dissemination was observed. This capacity for hematogenic
dissemination is in concordance with recent studies demonstrating the
existence of CTC in the blood of 20%–39% of patients with GBM
(Lombard et al., 2015; Sullivan et al., 2014). As occurrence of extra-
cranial/extraspinal metastasis is expected to increase as GBM treatment
becomes more efficient, our results support the validity of our model to
F IGURE 6 Numerical chromosome abnormalities increase throughout the transformation process. Metaphase spreads were prepared from
primary (1), low‐passage‐immortalized (2), high‐passage‐immortalized (3), GBM‐derived (4), and metastasis‐derived (5 and 6) cells. In all cases,
cells were spotted onto microscope slides and stained with 2% Wright in Gurr buffer (pH 7.0), and metaphase chromosomes were scored using
a Leica 2005 microscope under a 100X oil objective lens. (A) Distribution of chromosome number (percent) for each cell type. A dramatic
increase in the number of hyperploid cells is already present in low‐passage‐immortalized cells and maintained in the other cell types.
(B) Representative images of results presented in (A)
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mimic in vitro the natural course of the disease in vivo. It is also quite
remarkable that HP‐immortalized NSC have the same capacity to be
highly metastatic as cells obtained from primary GBM. This indicates that
metastatic genotype is acquired early in tumour progression as has been
already proposed (Bernards & Weinberg, 2002; van de Wouw
et al., 2002).
In summary, we have developed an experimental model that allows
recapitulating the process of transformation of mouse embryo NSC into
GBM‐producing cells in vitro. As most of the cells enter in senescence
when submitted to the 3T3 protocol (Almengló et al., 2020, and the
present study), we do not presently know whether all the SC present in
the culture or just a fraction of them are able to overcome senescence. In
other words, it remains to be elucidated whether all NSC have the ca-
pacity of immortalization, or only some of them, because of a transfor-
mation process. In any case, we have found that the transformation
process occurs with a 100% frequency, thus suggesting that oncogenic
transformation is the unavoidable fate for, at least, a population of NSC
when undergoing long‐term proliferation in vitro. Furthermore, the
transformation likely occurs because of the presence of serum factors in
the culture medium, thus highlighting the importance of maintaining the
NSC in an adequate environment. While it remains to be elucidated
whether a similar mechanism may be involved in the pathogenesis of
GBM in vivo, a warning should be made about the transplantation of
NSC as a tool for neural repair (Arce et al., 2013).
Finally, we also describe a novel model of gliomagenesis that re-
capitulates in vitro the transformation of primary MEA into cells that are
able to generate both GBM and heterotopic tumours in vivo (Figure 8b).
This model has two important advantages over current systems. First, it
can be used to recapitulate the pathogenesis of GBM and, therefore, to
elucidate the timeline of the mutations that accounts for the generation
of GBM. Second, it provides us with a valuable tool to test the effec-
tiveness of therapeutics at different times throughout the natural history
of the disease. This characteristic would help the development of per-
sonalized treatment strategies by tailoring drug effectiveness with mu-
tational profiles. Finally, given the ability of all cell types (including those
derived from GBM or heterotopic tumours) to form neurospheres when
placed on NBE conditions, they can be used to generate 3D organoid
culture systems (Kadoshima et al., 2013; Paşca et al., 2015) to capture
F IGURE 7 Cell proliferation progressively increases throughout the transformation process. (A) Primary (1), low‐passage‐immortalized (2),
high‐passage‐immortalized (3), GBM‐derived (4), and metastasis‐derived (5 and 6) cells were cultured, and cell number was determined by
crystal‐violet staining. A progressive increase in the growth rate was observed from 1 to 5–6. (B) Representative images of results presented in
panel A. (C) Ki67 staining in the different cell types. The percent of Ki67+ cells was determined after scoring them by immunocytochemistry.
(D) BrdU incorporation was determined by immunocytochemistry. In this case, each bar represents the mean + SEM of three experiments in
triplicate. *p < .05 versus primary cells. BrdU,; GBM,;
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the phenotypic and molecular particularities of GBM, as we have recently
shown (Gomez‐Randulfe et al., 2019).
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